humburger icon
A circle of white paper dolls holding hands on a green background


Home > Study Groups > Mucositis


Paolo Bossi


Paolo Bossi, MD

Hannah Wardill


Hannah Wardill, PhD

Mission and Goals

Mucositis refers to the inflammation and ulceration of the mucosal lining caused by anti-cancer therapies, typically seen in the mouth and gastrointestinal tract, resulting in signs and symptoms such as pain, xerostomia, dysphagia, diarrhea, infection, malnutrition and many more. It is common and highly burdensome but remains poorly managed.

The Mucositis Study Group’s major goal is to improve outcomes of patients experiencing oral and gastrointestinal mucositis. Working closely with the International Society of Oral Oncology (ISOO), our objectives are to improve the design and conduct of clinical investigations, disseminate up-to-date educational information regarding mucositis, and serve as a resource for investigators in basic science, clinical, and health services research, as well as for industrial collaborators, clinicians, and patients.

Topics of research within the Mucositis Study Group include:

  • Mucosal immunology and host-microbiome interactions
  • Enteric nervous system dysfunction
  • Symptom clusters related to mucosal damage
  • Mucositis assessment tools
  • Emerging oral and gastrointestinal toxicities caused by novel anti-cancer therapies

We are interested in diversifying our membership and encourage people from the following disciplines to consider becoming a member of the Mucositis Study Group:

  • Dentists and oral medicine specialists
  • Dieticians and other nutrition-based allied health professionals
  • Nurses
  • Pharmacists
  • Basic and translational scientists (e.g. microbiome scientists, immunologists)
  • Medical oncologists
  • Radiation oncologists
  • Haematologists
  • Gastroenterologists
  • AI/ML experts and bioinformaticians
Paolo Bossi, Brescia, Italy (2022)
“The Mucositis Study Group is a tremendous opportunity to get involved with the experts in this topic from all over the world.”
Sharon Elad, Rochester, NY, USA (2022)
“We, the Mucositis Study Group members, join forces to collaborate on research and to provide clinicians with better tools to assist their patients.”
Abhishek Kandwal, Dehradun, Uttarakhand, India (2022)
"Oral mucositis is a debilitating site effect of radiation therapy and chemotherapy. A standard protocol is very essential to provide relief in such patients”

How to Join

To join a study group, you must be a MASCC member. Members can belong to up to three study groups. 


Evidence-based clinical practice guidelines created or endorsed by the Mucositis Study Group


Scientific publications from the Mucositis Study Group

Educational Recordings

Gastrointestinal Complications of Immunotherapy and Targeted Agents Prevention and Treatment Options


Oral Complications of Immunotherapies and TKIs: Similarities and Differences to Conventional Oral Mucositis